Stock SVRA SAVARA INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Savara Inc.

Equities

SVRA

US8051111016

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
4.95 USD +8.08% Intraday chart for Savara Inc. +16.75% +5.32%
Apr. 12 Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection CI
Apr. 08 Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection
CI
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
BU
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024
CI
Savara Announces New Employment Inducement Grant
AQ
Savara Announces New Employment Inducement Grant
BU
Transcript : Savara Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
BU
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
BU
Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating
MT
JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target
MT
Savara Announces New Employment Inducement Grant
BU
Savara to Present at Two Upcoming Healthcare Conferences
BU
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing
MT
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing
MT
Savara Introduces aPAP ClearPath, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis
AQ
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
BU
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis
CI
Savara Added to the NASDAQ Biotechnology Index
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SVRA Stock
  4. News Savara Inc.